

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
9892	Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer	ETCTN-wide	Radiation	Gynecologic	https://clinicaltrials.gov/ct2/show/NCT02595879
9938	Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT02595931
10005	A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma	ETCTN-wide		Alveolar soft part sarcoma	https://clinicaltrials.gov/ct2/show/NCT03141684
10014	A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies	ETCTN-wide		Leukemia, Lymphoma, Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT02862275
10030	A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia	Limited		Leukemia	https://clinicaltrials.gov/ct2/show/NCT02879695
10056	A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma	ETCTN-wide	Radiation	Sarcoma	https://clinicaltrials.gov/ct2/show/NCT02923778
10057	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	ETCTN-wide		Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT02978625

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10061	A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03030378
10075	A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT03041688
10076	A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma	Limited		Myeloma	https://clinicaltrials.gov/ct2/show/NCT03031730
10096	A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)	ETCTN-wide	Radiation	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT03317392
10100	A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option	ETCTN-wide		Genitourinary	https://clinicaltrials.gov/ct2/show/NCT03237780
10129	A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors	ETCTN-wide		Brain, Gastrointestinal, Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT03212274

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10136	A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification	ETCTN-wide		Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT03253679
10144	A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects	ETCTN-wide		Genitourinary	https://clinicaltrials.gov/ct2/show/NCT03375307
10146	Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer	ETCTN-wide		Breast	https://clinicaltrials.gov/ct2/show/NCT03606967
10166	A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer	ETCTN-wide		Lung	https://clinicaltrials.gov/ct2/show/NCT03600701
10183	A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma	ETCTN-wide		Genitourinary	https://clinicaltrials.gov/ct2/show/NCT03854474
10186	A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma	ETCTN-wide	Radiation	Brain	https://clinicaltrials.gov/ct2/show/NCT03604978
10204	Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03816345
10208	A Phase I/II study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4	ETCTN-wide		Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT03816358

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
	and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma				
10211	A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer	ETCTN-wide		Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT03641313
10214	Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers	ETCTN-wide		Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT03816332
10216	A Phase Ib/II Study of Osimertinib and CB-839 in Patients with EGFR Mutant Non-Small Cell Lung Cancer	ETCTN-wide		Lung	https://clinicaltrials.gov/ct2/show/NCT03831932
10217	A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors	ETCTN-wide		Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT03842228
10221	Phase I/II Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors	Limited (Phase 1 only)		Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04317105
10222	A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors	ETCTN-wide		Gastrointestinal, Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT03878095
10246	A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Limited		Leukemia	https://clinicaltrials.gov/ct2/show/NCT03772925
10264	The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT03953898

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
	II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome				
10268	Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer	ETCTN-wide		Lung	https://clinicaltrials.gov/ct2/show/NCT03896503
10273	A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT03983824
10276	A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies	ETCTN-wide (in PII)	Radiation	Gastrointestinal, Solid tumors (dose escalation)	https://clinicaltrials.gov/ct2/show/NCT04068194
10285	Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination with Dual BRAF/MEK Inhibition in Patients with BRAF- Mutated Metastatic Melanoma who Progressed on Prior BRAF/MEK Inhibitor Therapy	ETCTN-wide		Skin and other melanoma	https://clinicaltrials.gov/ct2/show/NCT04557956?id=10285
10287	A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)	ETCTN-wide		Breast	https://clinicaltrials.gov/ct2/show/NCT03939897

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10291	A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	ETCTN-wide	Radiation	Breast	https://clinicaltrials.gov/ct2/show/NCT04052555
10292	DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT03907475
10299	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients	ETCTN-wide		Lymphoma, Solid tumors (no specified mutations)	Not available at this time.
10300	BLAST MRD AML-1: A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT04214249
10301	A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	ETCTN-wide	Radiation	Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04071236
10302	Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer	ETCTN-wide	Radiation	Breast	https://clinicaltrials.gov/ct2/show/NCT04090398

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10313	A Phase IB and Randomized Open-Label Phase II Study of M6620 in Combination with Carboplatin/Gemcitabine/Avelumab in Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology	ETCTN-wide		Lung	https://clinicaltrials.gov/ct2/show/NCT04216316
10324	A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)	Limited		Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04092270
10327	A Phase I Trial of MLN0128(TAK-228) and CB-839 HCL (telaglenastat) in Advanced NSCLC Patients	ETCTN-wide		Lung	https://clinicaltrials.gov/ct2/show/NCT04250545
10329	Phase I Sequential Trial of Agents Against DNA Repair (STAR)	Limited (Phase 1 only)		Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04197713
10330	A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma	ETCTN-wide		Sarcoma	https://clinicaltrials.gov/ct2/show/NCT04340843
10334	BLAST MRD AML-2: A Randomized Phase 2 Study of Venetoclax, Azacitadine, and Pembrolizumab Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT04284787
10335	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated	ETCTN-wide		Leukemia, Lymphoma	https://clinicaltrials.gov/ct2/show/NCT04301076

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
	Adult T-Cell Leukemia-Lymphoma (ATLL)				
10346	Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors	Limited		Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04294628
10347	A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)	ETCTN-wide		Lymphoma	https://clinicaltrials.gov/ct2/show/NCT04652960?id=10347&draw=2&rank=1
10355	A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies	ETCTN-wide		Solid tumors (mutations), solid tumor (dose escalation), gynecologic	https://clinicaltrials.gov/ct2/show/NCT04585958
10358	Phase 1/1B study of DS8201a in combination with ATR Inhibition (AZD6738) in advanced solid tumors with HER2 expression (DASH Trial)	ETCTN-wide		Gastrointestinal, Solid tumors (dose escalation), Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04704661
10366	A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma	ETCTN-wide	Radiation	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT04172532
10367	A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT04190550

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10371	A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response	ETCTN-wide		Solid tumors (mutations)	https://clinicaltrials.gov/ct2/show/NCT04550494
10382	A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer	Limited (Phase 1)		Breast	https://clinicaltrials.gov/ct2/show/NCT04345913
10384	A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma	ETCTN-wide		Lymphoma	https://clinicaltrials.gov/ct2/show/NCT04541017
10387	Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection	Limited		Sarcoma, Solid tumors (dose escalation)	https://clinicaltrials.gov/ct2/show/NCT04514484
10388	A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	ETCTN-wide	Radiation	Gastrointestinal, endocrine	https://clinicaltrials.gov/ct2/show/NCT04234568
10389	A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer	ETCTN-wide	Radiation	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT04460937
10398	A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma	ETCTN-wide		Sarcoma	https://clinicaltrials.gov/ct2/show/NCT04458922

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10401	A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma	ETCTN-wide		Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04494113
10402	BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)	ETCTN-wide		Gastrointestinal, Lung, Solid tumors (dose escalation), endocrine	https://clinicaltrials.gov/ct2/show/NCT04514497
10403	Phase 1 Trial of Gemcitabine Combined with the BAY1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer	ETCTN-wide		Gastrointestinal, Gynecologic, Solid Tumors (dose escalation)	https://clinicaltrials.gov/ct2/show/NCT04616534
10404	A Phase I Trial of the ATR Inhibitor BAY 1895344 in Combination with Cisplatin and with Cisplatin Plus Gemcitabine in Advanced Solid Tumors with an Emphasis on Urothelial Carcinoma	ETCTN-wide		Genitourinary, Solid tumors (dose escalation)	https://clinicaltrials.gov/ct2/show/NCT04491942
10405	Phase 1 Trial of BAY1895344 ATR Inhibitor Combined with Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma	ETCTN-wide	Radiation	Head and Neck Cancer	https://clinicaltrials.gov/ct2/show/NCT04576091
10406	Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers	ETCTN-wide		Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT04535401

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10410	A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer	ETCTN-wide	Radiation	Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT04406857
10411	Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)	ETCTN-wide		Sarcoma	https://clinicaltrials.gov/ct2/show/NCT04595747
10422	Abemaciclib and Olaparib for Recurrent Ovarian Cancer	ETCTN-wide		Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04633239?id=10422
10417	Clinical Evaluation of ASTX727 in Combination with Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT04817241
10450	A Phase 1b Study of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)	ETCTN-wide		Endocrine, Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT04750954
10434	Randomized Phase 2 Study of CPX-351 + Pomalidomide versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT04802161

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10433	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors	ETCTN-wide		Solid tumors (no specified mutations), Gynecologic	https://clinicaltrials.gov/ct2/show/NCT04840589
10440	A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis	ETCTN-wide		Myeloma	https://clinicaltrials.gov/ct2/show/NCT04847453
10466	A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer	ETCTN-wide		Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04981509
10476	A Randomized Phase 2 Study of combination Atezolizumab and Varlilumab with or without addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers	ETCTN-wide		Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT04941287
10483	Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	ETCTN-wide		Genitourinary	https://clinicaltrials.gov/ct2/show/NCT04963153
10445	Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Extensive-Stage Small Cell Lung Cancer	ETCTN-wide		Lung	https://clinicaltrials.gov/ct2/show/NCT05353439

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10499	Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas	ETCTN-wide		Lymphoma, Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05053971
10507	A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma	ETCTN-wide		Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05019716
10490	Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05142241
10492	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer	ETCTN-wide	Radiation	Head and neck	https://clinicaltrials.gov/ct2/show/NCT05172245
10496	A Phase II Trial of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	ETCTN-wide		Head and neck	https://clinicaltrials.gov/ct2/show/NCT05172258
10486	Phase 2 Trial of the Combination of the BET Inhibitor, ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET)	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05327010
10495	Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations	ETCTN-wide		Solid tumors (no specified mutations)	https://clinicaltrials.gov/ct2/show/NCT05372614

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10504	A Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)	ETCTN-wide		Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05333458
10508	A Phase 1/2 Study of the Combination of Oral DNMT Inhibition and Checkpoint Inhibition in Relapsed DLBCL and HL	ETCTN-wide		Lymphoma	https://clinicaltrials.gov/ct2/show/NCT05272384
10449	A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer	Limited (for dose escalation)		Breast	https://clinicaltrials.gov/ct2/show/NCT05111561
10480	Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients with Metastatic Triple-Negative Inflammatory Breast Cancer	ETCTN-wide (In PII)		Breast	https://clinicaltrials.gov/ct2/show/NCT05198843
10509	A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors	ETCTN-wide		ST escalation, Sarcoma	https://clinicaltrials.gov/ct2/show/NCT05372640
10512	A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer	Limited	Radiation	Lung	https://clinicaltrials.gov/ct2/show/NCT05198830
10237	A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents	Limited		Leukemia	https://clinicaltrials.gov/ct2/show/NCT03816319

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10464	A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer	ETCTN-wide		Gastrointestinal	https://clinicaltrials.gov/ct2/show/NCT05411094
10517	An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib with or Without Atezolizumab in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (NERA)	ETCTN-wide		Genitourinary	https://clinicaltrials.gov/ct2/show/NCT05564416
10525	A Phase 1b Trial of ZEN-3694 with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer	ETCTN-wide		Breast	https://clinicaltrials.gov/ct2/show/NCT05422794
10487	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation	ETCTN-wide		Genitourinary, Endocrine	Not available at this time.
10500	Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma	ETCTN-wide		Lymphoma	Not available at this time.
10528	Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors	ETCTN-wide		ST Mutations	Not available at this time.
10479	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors	ETCTN-wide		Endocrine, Gastrointestinal	Not available at this time.

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10505	A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma	ETCTN-wide		Brain	https://clinicaltrials.gov/ct2/show/NCT05432804
10527	A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774	ETCTN-wide		ST Mutations	Not available at this time.
10522	A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma	ETCTN-wide		Gastrointestinal	Not available at this time.
10538	Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial	ETCTN-wide		Leukemia	https://clinicaltrials.gov/ct2/show/NCT05600894
10546	Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer	ETCTN-wide		Breast	Not available at this time.
10553	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients	ETCTN-wide		Head and Neck	Not available at this time.
10558	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetium 177 dotatate alone for well-	ETCTN-wide		Endocrine	Not available at this time.

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
	differentiated somatostatin receptor-positive neuroendocrine tumors				
10561	Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab	Limited		Solid Tumors, NOS	Not available at this time.
10563	A phase 1 study of peposertib (M3814) and low-dose liposomal doxorubicin (Doxil®) in patients with metastatic leiomyosarcoma and other soft tissue sarcomas	ETCTN-wide		Sarcoma	Not available at this time.
10556	Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma	ETCTN-wide		Sarcoma	Not available at this time.
10597	A Phase 1 trial of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers	ETCTN-wide		Gynecologic	Not available at this time.
10577	Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors	Limited		Solid tumor (no specified mutations)	Not available at this time.
10572	A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774	Limited		ST Mutations	Not available at this time.
10551	Phase I/Ib Study of Anti-CD47 Magrolimab in Combination with Olaparib in BRCA Mutant Patients with Metastatic or Recurrent Solid Tumors	ETCTN-wide		ST mutations, ST escalation, Breast, Gynecologic, Genitourinary	Not available at this time.

All ETCTN Trials: Updated November 10, 2022 (Includes trials that are in review, approved, and active)

CTEP Trial ID	Title	Limited/ ETCTN-wide	Radiation Oncology	Disease Area(s)	ClinicalTrials.gov website (if available)
10590	NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab	ETCTN-wide		Lymphoma	Not available at this time.
10596	A Phase 1b Study of Menin Inhibitor SNDX-5613 with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease	ETCTN-wide		Leukemia	Not available at this time.
10579	Phase I Trial of ZEN-3694 in Combination with Capecitabine in Patients with Solid Tumors	Limited		Solid tumors (dose escalation), GI	Not available at this time. New
10601	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	ETCTN-wide		Lymphoma	Not available at this time. New